Comparison of efficacy of Erythropoietin Alpha with Erythropoietin Beta in Treatment of Anemia in Patients of End Stage Renal Disease on Hemodialysis
Abstract
Objective: To compare the efficacy of erythropoietin (EPO) alpha with erythropoietin beta in treatment of anemia in patients of end stage renal disease (ESRD) on hemodialysis.Methods
This Prospective Cohort was carried out in the Department of Nephrology, Allied hospital, Faisalabad from 11/06/2022 to 10/12/2022. 170 patients meeting the selection criteria were enrolled. Group A patients received erythropoietin alpha for 3 months. Group B patients received erythropoietin beta for 3 months. The dosage was administered subcutaneously. Efficacy was assessed after 3 months of treatment as per the operational definition.Results
Mean age in Group A was 45.79+10.91 and in Group B 44.74+11.28 years. Mean BMI of the patients in Group A was 27.36+2.69 and in Group B 27.42+2.83. Mean duration of dialysis in Group A was 2.91+1.18 years and in Group B 2.87+1.14 years. Efficacy in Group A was 17(20%) and in Group B 38(44.7%).Conclusion
The study concluded that erythropoietin beta is better than erythropoietin alpha in treatment of anemia in patients of ESRD on hemodialysis.Keywords:
End stage renal disease (ESRD), anemia, erythropoietin alpha, hemodialysis, erythropoietin beta, efficacy.Published
2025/11/21
Issue
This work is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License 
.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution BY-NC 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com